Upgrade to SI Premium - Free Trial

Biogen (BIIB) Announces Amended Agreement with Neurimmune Holding AG on Investigational Alzheimer's Disease Treatment Aducanumab

October 24, 2017 6:31 AM
Biogen (NASDAQ: BIIB) announced today that it has increased the profit potential on aducanumab, its Phase 3 investigational treatment for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News Mergers and Acquisitions

Next Articles